sumatriptan succinate · Endo Operations · NDA 022239
Sumavel Dosepro
Earliest generic entry, as listed · earliest of 2 marketed strengths
22 Nov 2026
1 of 2 marketed strengths has no unexpired patent or exclusivity listed; no marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 7776007.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7776007 | drug product · sets the listed date | 22 Nov 2026 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Enters 12-month window basis: patent · 022239-001Listed date 22 Nov 2026Detected 24 Oct 2026
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022239 · 001 · RLD · discontinued | solution, subcutaneous | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | 22 Nov 2026 |
| 022239 · 002 · RLD · discontinued | solution, subcutaneous | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | open |
Expired or delisted (1)
- US 7901385 · product · 31 Jul 2026